National Cancer Institute; Notice of Closed Meetings, 47652-47653 [2021-18399]

Download as PDF 47652 Federal Register / Vol. 86, No. 163 / Thursday, August 26, 2021 / Notices Development Plan (IDP) is an important step in helping a trainee’s career and professional development and is standard practice in graduate and postdoctoral education. An IDP is an effective tool for trainees to think about their career goals and skills needed to achieve them during their time at the NEI. Trainees work together with their research mentor to organize and summarize their research projects, consider career goals, and set training goals and expectations, both for the mentee and mentor. This information collection request is to implement an electronic Individual Development Plan (eIDP). The data collected comes from a detailed questionnaire focused on responses to professional goals and expectations while they are at the NEI. It is expected that the trainees will complete the eIDP annually and by doing so, it will help enhance the effectiveness of their training by setting clear goals that can be monitored not only by the trainee themselves but also by their mentor, the Training Director, and their Administrative Officer. In addition to this eIDP, the system will also implement an electronic exit survey. The data collected comes from a detailed questionnaire focused on responses to questions focused on trainee mentoring and professional experiences at the NEI as well as their plans after they depart. It is expected that the trainees will complete at the end of their tenure and that by doing so, the NEI Training Program can learn about ways to improve career development opportunities for future trainees as well as learn more about trainee job choices to better advise fellows. Additionally, we can use the survey to help determine mentor effectiveness and help identify problems in mentoring at the NEI. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 213. ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of respondent Average time per response (in hours) Total annual burden hour eIDP (Attachment 1) ......................... Exit Survey Part 1 (Attachment 2) .... Exit Survey Part 2 (Attachment 3) .... Individuals ........................................ Individuals ........................................ Individuals ........................................ 150 150 150 1 1 1 1 5/60 20/60 150 13 50 Total ........................................... ........................................................... 150 150 ........................ 213 Dated: August 19, 2021. Cesar E. Perez-Gonzalez, Training Director, National Eye Institute, National Institutes of Health. [FR Doc. 2021–18393 Filed 8–25–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings jbell on DSKJLSW7X2PROD with NOTICES Number of responses per respondent Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–6: NCI Clinical and Translational Cancer Research. Date: October 12, 2021. Time: 11:00 a.m. to 4:00 p.m. VerDate Sep<11>2014 17:30 Aug 25, 2021 Jkt 253001 Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W240, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Rockville, Maryland 20850, 240–276–5122, hasan.siddiqui@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–1: NCI Clinical and Translational Cancer Research. Date: October 28, 2021. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, 240–276–6372, zouzhiq@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Metastasis Research Network (U54). Date: October 28–29, 2021. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 7W238, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Byeong-Chel Lee, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Rockville, Maryland 20850, 240–276–7755, byeong-chel.lee@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Proteogenomic Tumor Analysis. Date: November 3, 2021. Time: 9:30 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W114, Rockville, Maryland 20850, 240–276–6371, decluej@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; R03 Omnibus and R21 Clinical and Translational Research. Date: November 3, 2021. Time: 10:00 a.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W556, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Kamal Datta, M.D., Scientific Review Officer, Program E:\FR\FM\26AUN1.SGM 26AUN1 Federal Register / Vol. 86, No. 163 / Thursday, August 26, 2021 / Notices Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W556, Rockville, Maryland 20850, 240–276–6526, kamal.datta@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Research Projects in Cancer Systems Biology (U01). Date: November 4, 2021. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Rockville, Maryland 20850, 240–276–6372, zouzhiq@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Institutional Training and Education Special Emphasis Panel. Date: November 4, 2021. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850, 240–276–6368, Stoicaa2@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 23, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–18399 Filed 8–25–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard jbell on DSKJLSW7X2PROD with NOTICES [Docket No. USCG–[USCG–2021–0042]] Revisions to Maritime Security Directive 104–6; Guidelines for U.S. Vessels Operating in High Risk Waters Coast Guard, DHS. Notice of availability. AGENCY: ACTION: VerDate Sep<11>2014 17:30 Aug 25, 2021 Jkt 253001 The Coast Guard announces the availability of Revision 8 to Maritime Security (MARSEC) Directive 104–6, which provides guidelines for U.S. vessels operating in high-risk waters (HRW) where acts of terrorism, piracy, and armed robbery against ships are prevalent. The directive contains security-sensitive information and, therefore, cannot be made available to the general public. U.S. vessel owners and operators who have needed to take action under previous versions of MARSEC Directive 104–6 should immediately contact their local Coast Guard Captain of the Port or District Commander for a copy of Revision 8. This revision contains important updates to HRW locations and organizational responsibilities regarding addressing security risks in those waters. SUMMARY: MARSEC Directive 104–6 (Revision 8) has been available since August 11, 2021. MARSEC Directive 104–6 (Revision 7) is no longer valid after that date. DATES: For information about this document call or email LCDR Michael Metz; U.S. Coast Guard, Office of Commercial Vessel Compliance; telephone 202–372–1236, email cvc.uscg@uscg.mil. FOR FURTHER INFORMATION CONTACT: Maritime Security (MARSEC) Directive 104–6 Revision 8 replaces Revision 7, previously signed on March 4, 2014. The new directive provides direction to U.S. flagged vessels operating in High Risk Waters (HRW) where acts of terrorism, piracy, and armed robbery against ships are prevalent. This revision reflects a change in organizational responsibilities and updates the list of regions identified as HRW. U.S. vessel owners and operators who have needed to take action under previous versions of MARSEC Directive 104–6 should immediately contact their local Coast Guard Captain of the Port or District Commander for a copy of Revision 8, which contains important updates to the locations of HRW and to the guidelines for addressing security risks in those waters. The Coast Guard advises owners and operators that, under Revision 8, they may need to take specific actions in accordance with MARSEC Directive 104–6 before their vessel enters HRW. This notice is issued under authority of 33 CFR 101.405(a)(2) and 5 U.S.C. 552(a). SUPPLEMENTARY INFORMATION: PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 47653 Dated: August 23, 2021. W.R. Arguin, Captain, U.S. Coast Guard, Director of Inspections and Compliance. [FR Doc. 2021–18391 Filed 8–25–21; 8:45 am] BILLING CODE 9110–04–P DEPARTMENT OF HOMELAND SECURITY Transportation Security Administration Revision of Agency Information Collection Activity Under OMB Review: Baseline Assessment for Security Enhancement (BASE) Program Transportation Security Administration, Homeland Security (DHS). ACTION: 30-Day notice. AGENCY: This notice announces that the Transportation Security Administration (TSA) has forwarded the Information Collection Request (ICR), Office of Management and Budget (OMB) control number 1652–0062, abstracted below, to OMB for review and approval of a revision to the currently approved collection under the Paperwork Reduction Act (PRA). The ICR describes the nature of the information collection and its expected burden. The collection allows TSA to conduct transportation security-related assessments during site visits with surface transportation security and operating officials. DATES: Send your comments by September 27, 2021. A comment to OMB is most effective if OMB receives it within 30 days of publication. ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under Review—Open for Public Comments’’ and by using the find function. FOR FURTHER INFORMATION CONTACT: Christina A. Walsh, TSA PRA Officer, Information Technology (IT), TSA–11, Transportation Security Administration, 6595 Springfield Center Drive, Springfield, VA 20598–6011; telephone (571) 227–2062; email TSAPRA@ tsa.dhs.gov. SUMMARY: TSA published a Federal Register notice, with a 60-day comment period soliciting comments, of the following collection of information on June 4, 2021, 86 FR 30065. SUPPLEMENTARY INFORMATION: E:\FR\FM\26AUN1.SGM 26AUN1

Agencies

[Federal Register Volume 86, Number 163 (Thursday, August 26, 2021)]
[Notices]
[Pages 47652-47653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-18399]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-6: NCI Clinical and Translational Cancer Research.
    Date: October 12, 2021.
    Time: 11:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W240, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Hasan Siddiqui, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W240, Rockville, Maryland 20850, 240-276-5122, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; SEP-1: NCI Clinical and Translational Cancer Research.
    Date: October 28, 2021.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W242, Rockville, Maryland 20850, 240-276-6372, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Metastasis Research Network (U54).
    Date: October 28-29, 2021.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W238, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Byeong-Chel Lee, Ph.D., Scientific Review 
Officer, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W238, Rockville, Maryland 20850, 240-276-7755, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Proteogenomic Tumor Analysis.
    Date: November 3, 2021.
    Time: 9:30 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W114, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review 
Officer, Research Technology and Contract Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W114, Rockville, Maryland 20850, 240-276-6371, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; R03 Omnibus and R21 Clinical and Translational Research.
    Date: November 3, 2021.
    Time: 10:00 a.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W556, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Kamal Datta, M.D., Scientific Review Officer, 
Program

[[Page 47653]]

Coordination and Referral Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W556, Rockville, Maryland 20850, 240-276-6526, [email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Research Projects in Cancer Systems Biology (U01).
    Date: November 4, 2021.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W242, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Zhiqiang Zou, M.D., Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W242, Rockville, Maryland 20850, 240-276-6372, 
[email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Institutional Training and Education Special Emphasis Panel.
    Date: November 4, 2021.
    Time: 1:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W234, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Adriana Stoica, Ph.D., Scientific Review 
Officer, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W234, Rockville, Maryland 20850, 240-276-6368, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 23, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-18399 Filed 8-25-21; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.